Dopaminergic Neurons in Parkinson’s Disease

Prediger, Rui Daniel; Bortolanza, Mariza; Issy, Ana Carolina; Santos, Bruno Lopes dos; Del‐Bel, Elaine; Raisman‐Vozari, Rita

doi:10.1007/978-1-4614-5836-4_7

Cited by 7 publications

(5 citation statements)

References 151 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Deterioration of the dopaminergic system is believed to be the main cause of PD motor symptoms. The nigrostriatal pathway seems to be the most affected, but the mesolimbic and mesocortical pathways also appear to be affected ( Vallone et al, 2000 ; Prediger et al, 2014 ). Deterioration of motor functions is associated with prominent loss of dopaminergic neurons in SN ( Fearnley and Lees, 1991 ; White et al, 2010 ), the decline in striatal DA transporters levels ( Miller et al, 1997 ), and reduction in striatal TH-positive axonal staining ( Ryoo et al, 1998 ).…”

Section: Dopaminergic Systemmentioning

confidence: 99%

The Biology and Pathobiology of Glutamatergic, Cholinergic, and Dopaminergic Signaling in the Aging Brain

Gąsiorowska

Wydrych

Drapich

et al. 2021

Front. Aging Neurosci.

View full text Add to dashboard Cite

The elderly population is growing worldwide, with important health and socioeconomic implications. Clinical and experimental studies on aging have uncovered numerous changes in the brain, such as decreased neurogenesis, increased synaptic defects, greater metabolic stress, and enhanced inflammation. These changes are associated with cognitive decline and neurobehavioral deficits. Although aging is not a disease, it is a significant risk factor for functional worsening, affective impairment, disease exaggeration, dementia, and general disease susceptibility. Conversely, life events related to mental stress and trauma can also lead to accelerated age-associated disorders and dementia. Here, we review human studies and studies on mice and rats, such as those modeling human neurodegenerative diseases, that have helped elucidate (1) the dynamics and mechanisms underlying the biological and pathological aging of the main projecting systems in the brain (glutamatergic, cholinergic, and dopaminergic) and (2) the effect of defective glutamatergic, cholinergic, and dopaminergic projection on disabilities associated with aging and neurodegenerative disorders, such as Alzheimer’s and Parkinson’s diseases. Detailed knowledge of the mechanisms of age-related diseases can be an important element in the development of effective ways of treatment. In this context, we briefly analyze which adverse changes associated with neurodegenerative diseases in the cholinergic, glutaminergic and dopaminergic systems could be targeted by therapeutic strategies developed as a result of our better understanding of these damaging mechanisms.

show abstract

Section: Dopaminergic Systemmentioning

confidence: 99%

The Biology and Pathobiology of Glutamatergic, Cholinergic, and Dopaminergic Signaling in the Aging Brain

Gąsiorowska

Wydrych

Drapich

et al. 2021

Front. Aging Neurosci.

View full text Add to dashboard Cite

show abstract

“…Parkinson’s disease (PD) is a neurodegenerative disease characterized by motor manifestation, autonomic disorder, sensorial symptoms and neurological disorder that compromises the patient’s quality of life (QoL) [ 1 , 2 ].…”

Section: Introductionmentioning

confidence: 99%

Medication Therapy Management Service for Patients with Parkinson’s Disease: A Before-and-After Study

et al. 2016

View full text Add to dashboard Cite

BackgroundParkinson’s disease (PD) is a neurodegenerative disease characterized by motor manifestations, autonomic and neurological disorders and sensorial symptoms. Medication therapy management (MTM) consists of a service undertaken by pharmacists to optimize pharmacological therapy results. This way, the pharmacist monitors the treatment prescribed by the doctor and formulates a healthcare plan to guarantee the treatment’s effectiveness, safety and convenience, thereby improving the patient’s quality of life (QoL).ObjectiveTo analyze the effect of MTM upon medicine-related problems, motor symptoms, autonomic disorders and QoL of patients with Parkinson’s disease, and describe the pharmaceutical interventions.MethodsQuasi-experimental uncontrolled before-and-after study carried out between September 2012 and March 2013 in a community pharmacy. Pharmacotherapy data were collected from medical prescriptions, patient diaries, medical charts and all the medicines (over-the-counter and prescription) brought by the patients to the appointment with the pharmacist. The medicine-related problems were classified as indication, effectiveness, safety and adherence. Adherence was measured through clinical interviews and the Morisky questionnaire. PD symptoms were assessed according to the patients’ and/or caregivers’ perceptions about the On/Off state of the motor symptoms and relief of the nonmotor symptoms. QoL was assessed using the PDQ-39 scores. The interventions were targeted to patients/caregivers and/or doctors, with pharmacological and non-pharmacological measures.ResultsSeventy patients were followed up, showing a decrease in medicine-related problems (1.67 ± 1.34 to 0.8 ± 0.9 (p < 0.001), positive impact on adherence (from 37 to 10 non-adherent patients, p < 0.001), QoL improvement related to emotional wellbeing (p = 0.012) and autonomic disorder. Most interventions were performed directly with the patients (73.8%), including non-pharmacological guidance (28.5%), pharmacological guidance (24.3%) and rescheduling (13.6%).ConclusionsTo carry out MTM with PD patients, the pharmacist’s expertise needs to transcend the technical knowledge about the PD pharmacological treatment. The study showed a positive effect with a decrease in the medicine-related problems after the interventions, especially improving adherence and patients’ QoL.

show abstract

“…The EOs acted as antioxidants, reducing oxidative stress biomarkers such as malondialdehyde, protein carbonyl content, and nitric oxide radicals in the plasma and brain of the treated mice [47]. This is an interesting result, since it has been demonstrated that in PD patients treated for a long time with L-dopa, the oxidative stress increases and promotes disease progression [48].…”

Section: Essential Oils and Neurodegenerative Diseasesmentioning

confidence: 88%

Essential Oil Molecules Can Break the Loop of Oxidative Stress in Neurodegenerative Diseases

Spisni,

Valerii,

Massimino

2023

Biology

View full text Add to dashboard Cite

Essential oils (EOs) are mixtures of volatile compounds, extracted from aromatic plants, with multiple activities including antioxidant and anti-inflammatory ones. EOs are complex mixtures easy to find on the market and with low costs. In this mini narrative review, we have collected the results of in vitro and in vivo studies, which tested these EOs on validated models of neurodegeneration and in particular of the two main neurodegenerative diseases (NDs) that afflict humans: Alzheimer’s and Parkinson’s. Since EO compositions can vary greatly, depending on the environmental conditions, plant cultivar, and extraction methods, we focused our attention to studies involving single EO molecules, and in particular those that have demonstrated the ability to cross the blood–brain barrier. These single EO molecules, alone or in defined mixtures, could be interesting new therapies to prevent or slow down oxidative and inflammatory processes which are common mechanisms that contribute to neuronal death in all NDs.

show abstract

Dopaminergic Neurons in Parkinson’s Disease

Cited by 7 publications

References 151 publications

The Biology and Pathobiology of Glutamatergic, Cholinergic, and Dopaminergic Signaling in the Aging Brain

The Biology and Pathobiology of Glutamatergic, Cholinergic, and Dopaminergic Signaling in the Aging Brain

Medication Therapy Management Service for Patients with Parkinson’s Disease: A Before-and-After Study

Essential Oil Molecules Can Break the Loop of Oxidative Stress in Neurodegenerative Diseases

Contact Info

Product

Resources

About